< Back to News

CHNA ETF Rebalance – February 2019

Feb. 12, 2019

February 11th marked the semi-annual rebalance and reconstitution of the China BioPharma ETF’s (Nasdaq: CHNA) underlying index. This happens in a few steps.

A committee of advisors that oversees the index gets together and determines the reconstitution, which means they decide if any new companies should be added.

For the February meeting, the committee has added three new companies:

  • Innovent Biologics (HKEX: 1801)
  • Shanghai Junshi Biosciences (HKEX: 1877)
  • WuXi AppTec (HKEX: 2359)


These additions replace Essex Bio-technology (HKEX: 1061) and Lee’s Pharmaceutical Holdings (HKEX: 950), which at the time of the review did not meet the index’s minimum liquidity threshold. Essex and Lee’s will be eligible for re-inclusion during future semi-annual meetings.

Once the index’s holdings have been finalized, a rebalance occurs according to the index’s modified equal-weighting methodology. Each constituent is weighted equally, subject to the following adjustments applied depending on a company’s market capitalization to emphasize the role of larger companies.


CHNA ETF then places trades to replicate those changes as closely as possible. View all holdings of the China BioPharma ETF.

As of the rebalance, the China BioPharma ETF now has 29 holdings compared to 28 during the previous six months.

I am excited to see biotech innovators listing on the Hong Kong Stock Exchange under new rules implemented last year. As more initial public offerings (IPOs) happen over time, eligible companies will be included just as Innovent, Junshi, and WuXi AppTec have been today. We welcome these new additions and are pleased to support their mission of improving the lives patients in China and around the world.

To help the fund’s investors and followers learn more about the companies, we have provided a brief background of their work and what sets them apart. The CHNA ETF is thrilled to welcome each of them to the fund.

Innovent Biologics (HKEX: 1801)

Innovent Biologics is based in Suzhou, China, and has been active in the research and development of biologic medicines since the company was founded in 2011. Biologics are different from traditional chemical drugs and tend to be more difficult to make because they are derived and produced from natural living organisms such as humans, animals, or microorganisms. In China, they are not yet as common as they are in the west. For example, Innovent’s Chief Operating Officer Qinwei Zhou recently mentioned during a presentation at the Endpoints/Pharmcube US-China Biopharma Innovation and Investment Summit that sales of monoclonal antibodies, one type of biologic, were only $1.7 billion USD in China in 2017 compared to $104 billion for the rest of the world.

The company already has one biologic medicine approved in China. On December 27th, 2018, Innovent’s anti-PD1 inhibitor sintilimab (trade name Tyvyt) was approved by the National Medical Products Administration (NMPA) for the treatment of classical Hodgkin lymphoma. This drug is in the same class as other well-known PD-1 inhibitors like Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo. Sintilimab is also in phase 3 trials for non-small cell lung cancer, esophageal cancer, and gastric cancer. Innovent is currently developing 20 innovative medicines, covering four major disease areas: oncology, ophthalmology, autoimmunity, and cardiovascular diseases. This includes many biosimilars (the equivalent to a generic of a biologic) such as ones that mimic the popular medicines Rituxan, Avastin, and Humira.

One impressive thing about Innovent is the number of partnerships it has struck with global pharmaceutical companies. The largest is with Eli Lilly. Across two different deals, Lilly has paid Innovent $56 million upfront and is offering up to $1.4 billion in potential milestones. The partnership covers the now approved sintilimab and other cancer medicines such as a cMet inhibitor and bispecific antibodies. Cancer is a specialty of Innovent – three cancer drugs it has discovered are approved for clinical trials in the United States. In addition to Lilly, Innovent has partnerships with Adimab, Hamni, and Incyte. The Incyte deal was announced in December of 2018 and allows Innovent to develop Incyte’s pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor) in China.

Shanghai Junshi Biosciences (HKEX: 1877)

Shanghai Junshi Biosciences was founded in 2012 and is based in the Zhangjiang Hi-Tech Park area of Shanghai. This is Shanghai’s equivalent to Kendall Square in Cambridge, where many biotech companies are centered. The company’s stock started trading on the Hong Kong Stock Exchange on December 24th, 2018. Like many entrepreneurs running Chinese biotech companies today, Junshi’s CEO Li Ning has extensive experience working in the industry globally. He earned his Ph.D. in preventative medicine from the University of Iowa, spent more than 12 years at the U.S. Food and Drug Administration, and also worked in industry as Vice President of Asia Regulatory Affairs for the French pharmaceutical giant Sanofi.

Like Innovent above, Junshi has been focused on the research and development of biologics. In fact, it was the first domestic Chinese company to earn approval for a PD-1 inhibitor from the National Medical Products Administration when its drug toripalimab (trade name Tuoyi) was approved for the treatment of advanced melanoma on December 17th, 2018. One thing that is interesting about the news is that Merck’s PD-1 inhibitor Keytruda was also approved in China for advanced melanoma so this indication might provide insights into how domestic Chinese companies compete against multinational imports. Junshi turned heads shortly after the December approval when it announced it would price Tuoyi at a deep discount to Keytruda, one-half to one-third the price depending on the patient’s body weight.

In addition to PD-1’s (which it is testing in up to 10 different cancer types), the company’s pipeline includes a PCSK9 inhibitor drug similar to Amgen’s Repatha that is in clinical trials for hyperlipidemia, a biosimilar to Humira that is in a pivotal study for rheumatoid arthritis, and an anti-BLyS monoclonal antibody that will be starting a trial for lupus. Preclinical (before human stage testing) candidates include cancer medicines targeting CTLA-4, TIGIT, and BTLA. Overall, Junshi currently has 13 biologics in its pipeline. The company also says it has ambitions to reach beyond these medicines and has highlighted small molecule drug discovery and antibody drug conjugates as other areas it will start to get into. In short, Junshi aims to be a leader in innovation-driven medicine.

WuXi AppTec (HKEX: 2359)

WuXi AppTec was founded in 2000 and is one of the world’s largest discovery, development, and manufacturing service providers for the drug and medical device industries. WuXi AppTec doesn’t develop and commercialize its own medicines and medical devices; it instead is a partner to other companies that aim to do that. Currently it has over 3,000 collaborations ongoing in over 30 different countries. This is an example of a Chinese life sciences company that isn’t a leader just in China, but throughout the entire world. It is an integral player in the global drug and medical device pipeline. The company’s main areas of focus currently are on small molecule research and development (R&D) and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing.

The idea behind its business model is that there are many companies and researchers that have good ideas for new drugs and medical devices, but it is not realistic or efficient for all of them to build the infrastructure to discover, develop, and manufacture them on their own. With a partner like WuXi AppTec, they can benefit from the scale and knowhow the company has built up over time. Today WuXi AppTec has 18,000 employees, 28 R&D sites and offices worldwide, and 6 million square feet of office, laboratory and manufacturing space. By partnering with WuXi AppTec, a drug developer or medical device company inherits all the expertise and knowhow that comes with this footprint. In a way, it allows smaller companies to do drug development efficiently and almost virtually if they so choose.

WuXi AppTec originally went public in May of 2018 when it listed shares on the Shanghai Stock Exchange. It then subsequently launched a secondary listing on the Hong Kong Stock Exchange on December 12, 2018. In WuXi AppTec, you have a large service provider that is integral to drug and medical device development globally, but not all investors might be able to gain exposure to it since the company is only listed on stock exchanges in Shanghai and Hong Kong. This is a good example of why we created the China BioPharma ETF. The life sciences industry is changing rapidly and leaders are coming from all around the world. The China BioPharma ETF, with its China focus and access to companies listed on the Hong Kong Stock Exchange and Nasdaq, is please to add this major service provider to the fund.

Thank you for your interest in the China BioPharma ETF. Please be sure to sign up for email alerts below if you would like to receive notification of news, company interviews, and research that we publish from time to time.

Opinions expressed are those of the author or Funds and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Fund holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell any security. Adimab, Amgen, Bristol-Myers Squibb, Eli Lilly, Hamni, Incyte, Merck, and Sanofi are not a holding of the Fund or affiliated with the Fund. The Shanghai Stock Exchange is one of the major stock exchanges in Mainland China.

  • Loncar Funds
  • P.O Box 15072
  • Lenexa, KS 66285
  • +1 800-617-0004
  • Contact Us

CNCR Prospectus CHNA Prospectus

A basis point is a common unit of measure for interest rates and other percentages in finance. One basis point is equal to 1/100th of 1%, or 0.01% (0.0001).

The Loncar Cancer Immunotherapy Index is an index of 30 securities that have a strategic focus on the area of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for the index can be found under the symbol “LCINDX” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

The Loncar China BioPharma Index is an index of 50 securities that have a strategic focus on advancing China’s biopharma industry. Quotes for the index can be found under the symbol “LCHINA” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

Holdings are subject to change.

The Hong Kong Stock Exchange (HKEX) is the primary stock exchange in the Hong Kong Special Administrative Region of China. Nasdaq is one of the primary stock exchanges in the United States.

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus, which may be obtained at Read the prospectus carefully before investing.

Investing involves risk. Principal loss is possible. The fund may trade at a premium or discount to NAV. CNCR will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained. The Fund may invest in foreign securities, which involve political, economic, currency risk, greater volatility, and differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed and may be affected by a general decline in market segments related to the index. The fund invests in securities included in, or representative of securities included in, the index, regardless of their investment merits. The performance of the fund may diverge from that of the Index and may experience tracking error to a greater extent than a fund that seeks to replicate an index. Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

RISK FOR THE CHNA ETF: The biopharmaceutical industry in China is strictly regulated and changes in such regulations, including banning or limiting certain products, may have a material adverse effect on the operations, revenues, and profitability of Biopharma Companies. The laws and regulations applicable to the process of administrative approval of medicine and its production in China require entities producing biopharma products to comply strictly with certain standards and specifications promulgated by the government. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the investment. Currency exchange rates can be very volatile and can change quickly and unpredictably. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability. Investments in non-U.S. securities also may be subject to withholding or other taxes and may be subject to additional trading, settlement, custodial, and operational risks. These and other factors can make investments in the Fund more volatile and potentially less liquid than other types of investments. To the extent the Fund invests a significant portion of its assets in the securities of companies of a single country or region, such as China, it is more likely to be impacted by events or conditions affecting that country or region. The Fund is a recently organized, non-diversified management investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund. The Fund is not actively managed and the Fund's sub-adviser would not sell shares of an equity security due to current or projected underperformance of a security, industry or sector, unless that security is removed from the Index or the selling of shares of that security is otherwise required upon a reconstitution of the Index in accordance with the Index methodology. To the extent the Fund invests more heavily in particular sectors of the economy, its performance will be especially sensitive to developments that significantly affect those sectors."

Diversification may not protect against market risk.

Exchange Traded Concepts, LLC serves as the investment advisor, and Vident Investment Advisory, LLC serves as a sub advisor to the fund. The Funds are distributed by Quasar Distributors, LLC, which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.